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Aims In the recently published DANPACE trial, incidence of atrial fibrillation (AF) was significantly higher with single-lead
atrial (AAIR) pacing than with dual-chamber (DDDR) pacing. The present analysis aimed to evaluate the importance
of baseline PQ-interval and percentage of ventricular pacing (VP) on AF.
Methods
and results
We analysed data on AF during follow-up in 1415 patients included in the DANPACE trial. In a subgroup of 650
patients with DDDR pacemaker, we studied whether %VP, baseline PQ-interval, and programmed atrio-ventricular
interval (AVI) was associated with AF burden measured as time in mode-switch (MS) detected by the pacemaker. In
the entire DANPACE study population, the incidence of AF was significantly higher in patients with baseline PQ-
interval .180 ms (P, 0.001). Among 650 patients with DDDR pacemaker, telemetry data were available for
1.337+ 786 days, %VP was 66+33%, AF was detected at planned follow-up in 160 patients (24.6%), MS occurred
in 422 patients (64.9%), and AF burden was marginally higher with baseline PQ-interval .180 ms (P ¼ 0.028). No
significant association was detected between %VP and %MS (Spearman’s r 0.056, P ¼ 0.154). %MS was not different
between minimal-paced programmed AVI ≤ 100 and .100 ms (median value), respectively (P ¼ 0.60).
Conclusions The present study indicates that a longer baseline PQ-interval is associated with an increased risk of AF in patients
with sick sinus syndrome. Atrial fibrillation burden is not associated with the percentage of VP or the length of the
programmed AVI.
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Introduction
In The Danish Multicenter Randomized Trial on Single Lead Atrial
Pacing vs. Dual Chamber Pacing in Sick Sinus Syndrome
(DANPACE), atrial fibrillation (AF) was more common in patients
treated with single-lead atrial (AAIR) pacing than in patients treated
with dual-chamber (DDDR) pacing.1 This was an unexpected
finding, as most previous studies have indicated that ventricular
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† Participants in The Danish Multicenter Randomized Trial on Single Lead Atrial Pacing versus Dual Chamber Pacing in Sick Sinus Syndrome (DANPACE) are listed in the Appendix.
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pacing (VP) increases the occurrence of AF.2 –4 A longer baseline
PQ-interval has been found to increase the risk of AF in population
studies.5,6 In the present study, we analysed the association
between baseline PQ-interval and AF in the DANPACE trial. Fur-
thermore, we analysed AF burden and its association with the
baseline PQ-interval, with VP and with the programmed atrioven-
tricular interval using the diagnostic algorithms in DDDR pace-
makers that collect information on the time in mode-switch
(MS) as a sensitive measure of the time spent in AF.7 –9
Methods
The DANPACE trial
The DANPACE trial was initiated and driven by the investigators.1 We
randomly assigned a total of 1.415 patients with sick sinus syndrome
(SSS) to AAIR pacing or DDDR pacing. The criteria for inclusion were:
symptomatic bradycardia and documented sino-atrial block or sinus
arrest with pauses .2 s or sinus bradycardia ,40 b.p.m. for .1 min
while awake; PR-interval ≤0.22 s if aged 18–70 years or PR-interval
≤0.26 s if aged ≥70 years; and QRS width ,0.12 s. The main exclusion
criteria were: atrio-ventricular block; bundle branch block; long-standing
persistent AF (.12 months); AF with QRS rate ,40 b.p.m. for ≥1 min
or pauses.3 s; a positive test for carotid sinus hypersensitivity; planned
cardiac surgery; or a life-expectancy shorter than 1 year. Documented
paroxysmal AF was not an exclusion criterion. Follow-up took place
after 3 months and again every year after implantation up to 10 years.
Mean follow-up was 5.4+2.6 years. No difference was found
between treatment groups with respect to the primary outcome,
death from any cause. Paroxysmal AF, defined as the first diagnosis of
AF detected in the 12-lead electrocardiogram (ECG) and verified by
the pacemaker telemetry at a planned follow-up visit, was a secondary
outcome measure. Paroxysmal AF was observed more frequently in
the AAIR group than in the DDDR group, hazard ratio 1.27, 95% confi-
dence intervals 1.03–1.56, P ¼ 0.024.1
The trial was conducted in accordance with the Helsinki Declaration
and approved by the regional Ethics Committee and the Danish Data
Protection Agency. All patients gave their written informed consent
before inclusion.
Study population
The analysis of the association between baseline PQ-interval and par-
oxysmal AF was studied in the entire DANPACE population. The ana-
lysis of time in AF was done in patients included in the DANPACE trial,
randomized to, and treated with DDDR pacing, in whom correspond-
ing data on the percentage of pacing in the ventricle (%VP) and the
percentage of time in mode-switch (%MS) during follow-up were avail-
able (DDDR cohort). In some patients, these data were available for
only part of the follow-up period.
Pacemaker implantation and programming
Contemporary DDDR pacemaker models from Boston Scientific, Med-
tronic, and St Jude Medical were used. A bipolar lead was implanted in the
right atrium and an additional lead was implanted in the right ventricle.
During the implantation, a sensed atrial signal exceeding 2.0 mV was
searched for. Patients with AF during implantation either underwent
direct current cardioversion or received a pacemaker system without
an atrial pacing test at the implanter’s discretion. The rate adaptive func-
tion was active in all pacemakers and programmed with a lower rate of
60 b.p.m. and an upper rate of 130 b.p.m. The maximum tracking rate
was individualized and MS was activated. Mode-switch occurred at the
default programming when the atrial rate exceeded 170–180 b.p.m.
for a given number of beats or period of time as defined in each pace-
maker type. The investigators were asked to program the atrial sensitivity
to 0.5 mV. The paced atrio-ventricular interval (AVI) was programmed
to 140–220 ms according to a pre-specified algorithm: The paced AVI
was initially programmed to a value 10% longer than either the interval
measured from the atrial pacing spike to start of the conducted QRS
complex at 60 b.p.m. or the PR interval if the sinus rate was faster than
60 b.p.m. If VP occurred with this programming, the paced AVI was grad-
ually increased in steps of 20 ms until VP ceased or until a maximum of
220 ms was reached. If VP still occurred at a programmed AVI of
220 ms, the paced AVI was shortened to a length of 140–160 ms, and
the atrio-ventricular hysteresis function was activated to allow automatic
search for intrinsic atrio-ventricular conduction with an AVI of 220 ms.
The AVI after sensed atrial beats was set 20–30 ms shorter than the
paced AVI, and AVI automatically shortened during rate increases.
Data from the pacemaker memory
At each planned follow-up visit, a printout was made of the pacemaker
memory showing data accumulated since the previous resetting of the
memory. The %VP at each follow-up was calculated using the numbers
of paced and sensed beats. The mean %VP throughout the total
follow-up period was computed for each patient by calculating the
mean of these values, and used for the statistical analysis. The %MS
was calculated for each patient as the time in MS relative to the
total telemetry time recorded in the pacemaker.
Statistical analysis
Cumulative event rates of AF detected at planned follow-up visits were
calculated for patients randomized into the two treatments groups
with baseline PQ-interval ≥180 ms and ,180 ms (median) by the
Kaplan–Meier method. In the DDDR cohort, cumulative event rates
of AF detected at planned follow-up visits as well as of AF detected
as the first MS occurrence were calculated by the Kaplan–Meier
method. Corresponding values of %VP and %MS were introduced in
a scatter plot and non-parametric regression analysis was done to
evaluate the association between %VP and AF burden. Regression
was done also after stratifying for prior AF before pacemaker implant-
ation. An association between baseline PQ-interval and %MS was
searched for by means of non-parametric regression analysis. Distribu-
tions of %MS were compared between patients with baseline
PQ-interval ≤180 ms and .180 ms (median) and between patients
with minimal paced AVI ≤ 100 ms and .100 ms (median), respective-
ly. Statistical tests were two-tailed. Categorical variables were com-
pared by means of the Pearson’s x2 test and continuous variables by
means of the Mann–Whitney test. Two-sided P, 0.05 was consid-
ered significant. Mean+ SD are reported for continuous data, other-
wise median (percentiles). Data management was done using SIR/
DBMS and SIR/FORMS (SIR Database Software), and statistical analysis
was performed using SPSS/PASW version 18, BMDP release 8.1, and
STATA version 11.
Results
Population
Baseline data for the entire DANPACE population as well as for
the DDDR cohort (N ¼ 650) are presented in Table 1. In the data-
base, 3.573 follow-up visits were recorded in the DDDR cohort,
and 2.975 (83.3%) of these visits contributed with information
on %VP and %MS. The patients contributed with data from a
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mean of 4.6+2.2 follow-up visits and mean cumulative telemetry
periods of 1.337+786 days. No significant differences were
observed in the use of medication with potential effect on the
AF-burden between treatments groups at baseline (Table 1) or
at last follow-up (P. 0.40 for all).1
Atrial fibrillation
In the entire DANPACE population, mean follow-up to first
episode of AF or to last follow-up was 3.6+2.5 years. The inci-
dence of AF was higher among patients with a baseline PQ-interval
.180 ms (P, 0.001). Analysing the effects of randomization and
baseline PQ-interval on AF during follow-up, there was a trend
towards interaction between the two parameters, indicating that
the effect of pacing mode predominantly was observed among
patients with baseline PQ. 180 ms [P (randomization)¼0.035,
P(PQ) , 0.001; introducing an interaction link: P
(randomization)¼0.80, P(PQ) , 0.001, P (interaction)¼0.084].
Kaplan–Meier plots for the four groups are shown in Figure 1.
Pacemaker memory data collected during follow-up and data on
pacemaker programming and atrial sensed signals in the DDDR
cohort are shown in Table 2. During follow-up, 160 patients
(24.6%) had AF detected in 12-lead ECG at planned follow-up
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Table 1 Baseline characteristics
Characteristic AAIR pacing DDDR pacing DDDR cohort
(N 5 707) (N 5 708) (N 5 650)
Female gender—no. (%) 472 (66.8) 441 (62.3) 402 (61.8)
Age-years (mean+ SD) 73.5+11.2 72.4+11.4 72.3+11.5
Prior history of atrial fibrillation—no. (%) 303 (42.9) 318 (44.9) 294 (45.2)
Hypertension—no. (%) 241 (34.1) 239 (33.8) 217 (33.4)
Previous myocardial infarction—no. (%) 94 (13.3) 90(12.7) 78 (12.0)
Diabetes—no. (%) 68 (9.6) 72 (10.2) 67 (10.3)
Previous transient cerebral ischaemia—no. (%) 35 (5.0) 37 (5.2) 33 (5.1)
Previous stroke—no. (%) 61 (8.6) 53 (7.5) 50 (7.7)
LVEF reduced (,50%), no. (%) 59 (10.6) 54 (9.5) 46 (8.8)
LVEDD—mm (mean+ SD) 47.7+7.3 47.8+7.3 47.9+7.2
Left atrial diameter—mm (mean+ SD) 39.3+6.5 38.8+6.4 38.8+6.4
Symptoms before pacemaker—no. (%)
Syncopes 359 (50.8) 349 (49.3) 319 (49.1)
Dizzy spells 597 (84.4) 587 (82.9) 545 (83.8)
Heart failure 86 (12.2) 79 (11.2) 71 (10.9)
≥2 of the above three symptoms 317 (44.8) 291 (41.1) 269 (41.4)
Medication at randomization—no. (%)
Oral anticoagulation 108 (15.3) 89 (12.6) 80 (12.3)
Aspirin 369 (52.2) 361 (51.1) 324 (49.9)
Beta-blocker other than sotalol 159 (22.5) 132 (18.7) 118 (18.2)
Calcium-channel blocker 137 (19.4) 142 (20.1) 127 (19.5)
Digoxin 73 (10.3) 62 (8.8) 51 (7.8)
Class I or III Antiarrhythmics 82 (11.6) 88 (12.4) 82 (12.6)
Angiotensin-converting enzyme inhibitors 160 (22.6) 170 (24.0) 147 (22.6)
Diuretics 304 (43.0) 263 (37.2) 236 (36.3)
NYHA functional class—no. (%)
I 503 (71.4) 522 (73.9) 485 (74.7)
II 172 (24.4) 158 (22.4) 146 (22.5)
III– IV 29 (4.1) 26 (3.7) 18 (2.8)
Wenckebach block point ≥100 b.p.m. (%) 611 (94.1) 581 (91.6) 543 (92.2)
PQ interval (ms) 179+29 179+30 179+30
Stimulus-Q interval (ms) 228+53 232+59 232+59
Baseline characteristics are shown for the entire DANPACE population and for the subgroup of patients in the DDDR group where data on mode-switch and percentage of
ventricular pacing were available (the DDDR cohort).
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; NYHA, New York Heart Association; Stimulus-Q interval, the interval from atrial pacing
(AAIR) to start of the QRS complex.
The data were not complete for LVEF reduced (n ¼ 1127), LVEDD (n ¼ 986), left atrial diameter (n ¼ 1023), medications except calcium channel blocker (n ¼ 1414), NYHA
functional class (n ¼ 1410), Wenckebach block point ≥100 b.p.m. (n ¼ 1283), PQ-interval (n ¼ 1351) and Stimulus-Q interval (n ¼ 1039). In the DDDR cohort, the data were
not complete for LVEF reduced (n ¼ 524), LVEDD (n ¼ 465), left atrial diameter (n ¼ 475), aspirin (n ¼ 649), NYHA functional class (n ¼ 649), Wenckebach block point
≥100 b.p.m. (n ¼ 589), PQ-interval (n ¼ 628), and stimulus-Q interval (n ¼ 468).
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visits. In a total of 422 patients (64.9%), AF was detected as MS
during follow-up (Figure 2). The median time in MS was 1 day
(0.08% of observation time), 60, 70, 80, 90, and 95% percentiles
were: 6.85 days (0.61%), 30.3 days (2.74%), 95.1 days (10.1%),
293.5 days (29.8%), and 654.5 days (48.7%), respectively.
Mode-switch was detected in 154 of 160 patients (96.3%) who
had AF detected at planned follow-up visits. In the remaining six
patients, AF was reported in the case record forms at planned
follow-up visits, but no MS was detected. The explanations for
this disparity were: in three patients, no ECG documentation for
AF could be confirmed; in one patient, the atrial sensitivity had
been programmed to a value higher than atrial sensed signals of
0.1–0.2 mV during AF; in one patient, reprogramming to single-
lead VP (VVIR) had been done at a non-planned ambulatory visit
before the first detection of AF in the study, and therefore no
MS data were collected; and in one patient data on %MS
and %VP were missing from that part of the follow-up period
when AF was detected. Among the patients without AF documen-
ted in the 12-lead ECG at planned follow-up visits, MS still oc-
curred in 268 of 490 patients (54.7%). % MS was significantly
higher in patients with AF before pacemaker implantation
(Table 2). Furthermore, %MS was significantly higher in the group
of patients who had AF detected at planned follow-up visits
[15.4 (5.7, 39.7, 61.1) vs. 0.005 (0, 0.5, 4.2) %, Z ¼ 215.8, P,
0.001, median (25, 75, 90) % reported].
Correlation between ventricular pacing
and atrial fibrillation
A scatter plot showing the corresponding values of %VP and %MS
for each patient is shown in Figure 3. Visually, no clear pattern was
seen. Statistically, no significant linear association was detected
between %VP and %MS in the regression analysis (Spearman’s r
0.056, P ¼ 0.154). Nor was there any significant correlation
between %VP and %MS in the patients without AF prior to pace-
maker implantation (Spearman’s r 0.073, P ¼ 0.171) or in the
patients who had AF prior to pacemaker implantation (Spearman’s
r 20.003, P ¼ 0.961). There was no significant linear correlation
between baseline PQ-interval and %MS (Spearman’s r 0.062, P ¼
0.123). Dichotomizing the population into those with baseline
PQ-interval ≤180 ms and .180 ms (median), the %MS was mar-
ginally higher with PQ. 180 ms (P ¼ 0.028, Mann–Whitney test)
(Figure 4). %VP was significantly higher in the subgroup with PQ .
180 ms (79+27 vs. 55+34%, P, 0.001). No difference in distri-
bution of %MS was detected between patients programmed with a
minimal paced AVI ≤ 100 ms and .100 ms (median) (P ¼ 0.60)
(Figure 4).
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PQ £ 180ms, DDDR
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AAIR £ l80    392       301          185             102                  38
DDDR £ 180   385       280          189              95                      34
AAIR > 180    277        178           106               51                   9
DDDR > l80    297        210           133               61                   18
Figure 1 Kaplan–Meier plots showing the incidence of atrial
fibrillation detected in the 12-lead electrocardiogram at planned
follow-up visits in patients randomized to AAIR and DDDR
pacing dichotomized into groups with baseline PQ-interval
≤180 ms and .180 ms, respectively.
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Table 2 Pacemaker memory data and pacemaker programming
No AF before PM AF before PM P value
N5 356 N5 294
Total telemetry time—days (mean+ SD) 1.376+775 1.291+799 0.15
Time in MS—days (median [25, 75, 90 percentiles]) 0 [0, 4, 77] 31 [1, 166, 504] ,0.001
%MS—(median [25, 75, 90 percentiles]) 0 [0, 0.3, 7.1] 2.9 [0.04, 16.2, 42.6] ,0.001
%VP (mean+ SD) 65+33% 66+33% 0.95
Atrial sensed signal—mV (mean+ SD)
Baseline 3.3+1.5 3.4+1.8 0.84
First follow-up 3.1+1.4 3.0+1.5 0.46
Latest follow-up 2.8+1.4 2.3+1.5 ,0.001
Atrial sensitivity programmed—mV (mean+ SD)
First follow-up 0.59+0.46 0.60+0.40 0.34
Latest follow-up 0.57+0.43 0.54+0.27 0.034
Data from the pacemaker memory collected during follow-up and details of pacemaker programming in the DDDR cohort, divided into patients with and without documented AF
before pacemaker implantation, respectively.
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Discussion
The present study indicates that a longer baseline PQ-interval is
associated with an increased risk of AF in patients with SSS, espe-
cially if treated with AAIR pacing. The study is the first to evaluate
burden of AF as measured by the pacemaker telemetry during
long-term follow-up in a large cohort of patients with SSS. Atrial
fibrillation burden was not found associated with the percentage
of VP or with the programmed AVI.
The present findings are in accordance with the results of the
DANPACE trial, where the incidence of AF was lower with
DDDR pacing than with AAIR pacing.1 In the DANPACE trial,
the most important predictor of AF was prior AF. This finding is
confirmed in the present analysis, and accords with previous
studies.10,11
The benefit of DDDR pacing on AF in the DANPACE trial was
predominantly observed in the patients with a longer PQ-interval
at baseline. We observed an only marginally higher AF burden in
that subgroup with the longer PQ-interval in the DDDR cohort,
indicating that DDDR pacing protects against AF in case of a
longer PQ-interval. Patients with SSS and prolonged PQ-interval
therefore should be treated with DDDR pacing with an individually
programmed moderately prolonged AVI. These results accords
with the findings in a large community-based cohort study,
where a PQ-interval longer than 200 ms was associated with a
doubled risk of later AF as compared with a shorter PQ-interval.6
The most likely explanation of excess AF in the AAIR group is the
prolonged atrio-ventricular conduction often observed with atrial
pacing, resulting in reduced ventricular pre-load and mitral regur-
gitation.12 Recently, the total atrial conduction time has been
found to be a very strong predictor of AF.13,14 The prolonged
PQ interval probably also reflects a prolonged atrial conduction
time likely to be caused by atrial fibrosis and atrial dilatation,
that may be involved in the substrate for AF.
We found no indication, that atrio-ventricular synchronous VP
increased AF as compared with AAIR pacing. Our findings are in
Years from randomization
Fr
e
e
do
m
 fr
om
 a
tri
al
 fi
br
illa
tio
n 
(%
)
0
100
75
50
25
0
2 4 6 8
No. at risk
Mode-switch     650        257            145                63                    14
ECG follow-up  650        489            324               156                     51
Mode-switch
ECG follow-up
Figure 2 Kaplan–Meier plots showing the freedom from atrial
fibrillation detected in the 12-lead electrocardiogram at planned
follow-up visits (upper) and atrial fibrillation detected as
mode-switch (lower), respectively in the DDDR cohort. Time
until a first mode-switch—event was the date of planned follow-
up when it was observed that mode-switch had occurred for the
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Figure 3 Scatter plot showing corresponding values of percentage of ventricular pacing (%VP) and percentage of time in mode-switch (%MS)
as a measure of atrial fibrillation burden during follow-up. The regression line is shown (dashed line).
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accordance with recent analysis of data from two short-term studies
evaluating AF burden in patients with DDDR pacemakers.15–17
However, the finding of no association between VP and AF was un-
expected and in contrast to most previous studies as well as to the
general opinion. In two small randomized trials, AF was less
common with AAIR pacing than with VVIR pacing11,18 and DDDR
pacing.3,19 However, in both these studies the sample sizes were
small, and AF was detected only in ECG’s at planned follow-up
visits. In a post hoc analysis of data from the Mode Selection Trial in
Sinus-Node Dysfunction (MOST), statistical modelling indicated
that the risk of AF detected during follow-up increased by 1% for
each 1% increase in %VP in the DDDR mode.2 The confidence inter-
vals for these estimated risks were, however, very wide, and the as-
sociation was not present with %VP exceeding 85%.
Atrio-ventricular intervals of 120–200 ms were programmed,
resulting in a median %VP of 90%.2 In contrast, we used individually
programmed moderately prolonged AVI resulting in a mean of 65%
VP and the most sensitive method to detect burden of AF. In the ran-
domized SAVE PACe trial comparing conventional DDDR pacing
with DDDR pacing enabling pacemaker algorithms to promote in-
trinsic AV conduction and minimize VP, persistent AF was significant-
ly less frequent in the latter group, indicating that VP increases AF.4
Also this seems to be in contrast with the present findings. Most
likely, the differences in pacemaker programming and AF-endpoints
used may explain the disparities in results. In the SAVE PACe trial,
very short AVI resulting in 99% VP were programmed in the conven-
tional DDDR arm, probably resulting in a considerable degree of
ventricular desynchronization in many of the patients. Additionally,
Percentage of patients
0 10 20 30 40 0 10 20 30 40
PQ-interval £ 180ms
100
80
60
40
20
0
PQ-interval > 180ms
M
od
e-
sw
itc
h 
tim
e 
(%
)
Percentage of patients
0 10 20 30 40 0 10 20 30 40
Minimum paced AV-interval £ 100ms Minimum paced AV-interval > 100ms
100
80
60
40
20
0
M
od
e-
sw
itc
h 
tim
e 
(%
)
A
B
Figure 4 Distributions of atrial fibrillation burden as time in mode-switch (%MS) after dichotomizing the DDDR cohort with respect to base-
line PQ-interval ≤180 ms and .180 ms (A) and the minimal programmed paced AV-interval ≤100 ms and .100 ms (B), respectively.
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the higher percentage of atrial pacing in the SAVE PACe trial (median
71%) than in the DANPACE trial (in mean 59%) may add to explain
the differences in results as atrial pacing may cause interatrial dyssyn-
chrony, potentially important for AF. The present study indicates
that AF burden is without association to percentage of VP when
an individually programmed moderately prolonged AVI is used, sug-
gesting this pacing mode as a good alternative to DDDR pacemakers
with automated features to minimize VP. The algorithms used to
minimize VP in rare cases allows inadvertent bradycardia20 and
pose a small risk of potentially lethal bradycardia-related
tachy-arrhythmias.21– 23 No direct comparison has, however,
been done between these two pacing modes.
The pathophysiology of AF is very complex and as yet not fully
understood. Disease states as hypertension and mitral valve regur-
gitation causing higher atrial pressures and increased atrial wall
stress is associated with atrial dilatation and AF.24–28 It is well
established that VVIR pacing disrupting the atrio-ventricular syn-
chrony is associated with increased rates of AF,10,11,29,30 and this
can be explained by the mitral regurgitation and the increases in
atrial pressures induced by asynchronous VP against closed atrio-
ventricular valves.31,32 Atrio-ventricular synchronous VP with full
capture of the ventricles also results in higher atrial pressures31–
33 and increased incidence of persistent AF, as indicated by the
SAVE PACe trial.4 Early studies have indicated that cardiac
output and pulmonary capillary wedge pressure during DDD
pacing differ between individuals with various AVI.34,35 We did
not find any indication in the present analysis that shorter AVI
caused a higher AF burden than longer AVI. That may be explained
by the fact, that very short AVI were avoided in our trial. Very
recently, it was demonstrated that VP with full ventricular
capture, delivered after a longer AVI that allowed completion of
the atrial contraction, had no detrimental effects on the left
atrial function and size in patients with preserved left ventricular
function,36 supporting the findings in the present study.
In the group of patients with AF before pacemaker implantation,
we observed a decrease in the magnitude of the atrial sensed
signals during follow-up. This finding probably reflects some
degree of progression over time in the atrial substrate for AF.
The observational nature of the present analysis does not allow
us to conclude whether this alteration in atrial substrate is a
result of AF and/or contributes to AF.
As expected, the detection of AF by means of MS was found to
be much more sensitive than obtaining an ECG once per year. Pre-
vious reports have documented, that MS is a valid method to
detect AF with a high sensitivity and a high specificity.7– 9 Inappro-
priate MS can occur because of over sensing of far-field R-wave or
near-field P-waves,9 and failure of MS is observed due to under
sensing of small atrial signals or atrial blanking. In the present
cohort, low atrial sensitivity was programmed throughout the
study period, and atrial sensed signals remained more than four-
fold higher than programmed sensitivity. We used different pace-
maker models from different manufacturers, reflecting real life in
most centres.
Limitations
The present analysis does not represent a randomized comparison
of low vs. high frequency of VP. However, data were collected
prospectively within the frames of a randomized multicentre
trial, documenting the individual AF burden during long-term
follow-up in a large cohort of patients with SSS treated with con-
temporary DDDR pacemakers from different manufacturers. Ac-
curacy of MS was not evaluated in our study, but we find it
unlikely that any systematic errors in pacemaker programming or
any systematic incorrect MS influenced the accuracy of MS signifi-
cantly and thereby the conclusions in the present study. Data
on %VP and %MS are missing for some of the patients during
parts of the follow-up period. One of the reasons for that can
be reprogramming to VVIR pacing mode because of AF. Therefore,
AF burden may be slightly underestimated in the present study.
We find it unlikely, that this underestimation correlates with VP
thereby affecting the results. We did not collect information on
whether the VP delivered caused full ventricular capture, fusion,
or pseudofusion during the study period. It had been possible to
record that from ECG’s at ambulatory follow-up visits, but not
from the pacemakers. Therefore, only very limited and not neces-
sarily representative information could be gained on that topic.
Conclusion
The present study indicates that a longer baseline PQ-interval is
associated with an increased risk of AF in patients with SSS, espe-
cially if treated with AAIR pacing. Atrial fibrillation burden was not
found associated with the percentage of VP or with the pro-
grammed AVI.
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